MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.ahjo.2026.100781

Медицинская библиотека · American heart journal plus : cardiology research and practice · 2026

Adjunctive Eptifibatide Administration in ACS Patients Undergoing Percutaneous Coronary Intervention: A Randomized Comparison of Bolus-only Versus Standard Therapy.

Baharvand Fatemeh, Dadras Maedeh, Salari Arsalan, Parvaneh Shiva, Ashouri Asieh, Mirrazeghi Fatemeh, Aris Amir, Jenab Yaser

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

Guidelines do not recommend routine glycoprotein IIb/IIIa inhibitors (GPIs), reserving them for high thrombotic-risk or bailout cases. Most acute coronary syndrome (ACS) patients undergoing percutaneous coronary intervention (PCI) are already on dual antiplatelet therapy (aspirin plus clopidogrel). GPIs thus act as adjunctive therapy, providing short-term platelet inhibition. The optimal strategy, bolus-only versus bolus-plus-infusion, remains uncertain, especially in patients at higher bleeding risk.

OBJECTIVE

To evaluate whether bolus-only eptifibatide provides ischemic protection comparable to standard bolus-plus-infusion while reducing bleeding in ACS patients undergoing PCI.

METHODS

In this open-label, randomized trial, 183 ACS patients on aspirin and clopidogrel undergoing PCI received bolus-only eptifibatide (Group A, n = 102) or bolus plus continuous infusion (Group B, n = 81) and were followed for 90 days. The primary outcome, major adverse cardiac events (MACE), included cardiac death, recurrent myocardial infarction, stent thrombosis, or repeat target-vessel revascularization. Secondary endpoints included left ventricular function, mechanical/electrical complications, and bleeding. Major bleeding was defined by TIMI criteria; minor bleeding included clinically apparent non-life-threatening events.

RESULTS

MACE rates were similar (2.0% vs. 2.5%; p = 0.87). No major bleeding occurred. Left ventricular ejection fraction improved in both groups without significant difference (p = 0.52). Minor bleeding was lower in the bolus-only group (1.0% vs. 8.6%; p = 0.02). Electrical complications were infrequent and comparable.

CONCLUSIONS

In ACS patients on dual antiplatelet therapy, bolus-only eptifibatide provides ischemic protection comparable to bolus-plus-infusion while reducing minor bleeding, supporting a simplified adjunctive strategy in high thrombotic-risk patients undergoing PCI.

Для цитирования: Baharvand Fatemeh, Dadras Maedeh, Salari Arsalan, Parvaneh Shiva, Ashouri Asieh, Mirrazeghi Fatemeh, Aris Amir, Jenab Yaser. Adjunctive Eptifibatide Administration in ACS Patients Undergoing Percutaneous Coronary Intervention: A Randomized Comparison of Bolus-only Versus Standard Therapy.. American heart journal plus : cardiology research and practice. 2026. DOI: 10.1016/j.ahjo.2026.100781.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.